EGFR and cancer: Compared with the αvβ3− or the control groups, the integrin αvβ3+ cancer cells showed significant EGFR inhibitors resistance (Figure 1C–E), suggesting that the expression of integrin αvβ3 are highly correlated to the EGFR-associated drugs resistance in NSCLC.